Understanding interleukin 11 as a disease gene and therapeutic target.
fibrosis
inflammation
therapeutics
Journal
The Biochemical journal
ISSN: 1470-8728
Titre abrégé: Biochem J
Pays: England
ID NLM: 2984726R
Informations de publication
Date de publication:
13 Dec 2023
13 Dec 2023
Historique:
received:
16
09
2023
revised:
13
11
2023
accepted:
27
11
2023
medline:
7
12
2023
pubmed:
6
12
2023
entrez:
6
12
2023
Statut:
ppublish
Résumé
Interleukin 11 (IL11) is an elusive member of the IL6 family of cytokines. While initially thought to be a haematopoietic and cytoprotective factor, more recent data show instead that IL11 is redundant for haematopoiesis and toxic. In this review, the reasons that led to the original misunderstandings of IL11 biology, which are now understandable, are explained with particular attention on the use of recombinant human IL11 in mice and humans. Following tissue injury, as part of an evolutionary ancient homeostatic response, IL11 is secreted from damaged mammalian cells to signal via JAK/STAT3, ERK/P90RSK, LKB1/mTOR and GSK3β/SNAI1 in autocrine and paracrine. This activates a program of mesenchymal transition of epithelial, stromal, and endothelial cells to cause inflammation, fibrosis, and stalled endogenous tissue repair, leading to organ failure. The role of IL11 signalling in cell- and organ-specific pathobiology is described, the large unknowns about IL11 biology are discussed and the promise of targeting IL11 signalling as a therapeutic approach is reviewed.
Identifiants
pubmed: 38054591
pii: 233798
doi: 10.1042/BCJ20220160
doi:
Substances chimiques
Interleukin-11
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1987-2008Informations de copyright
© 2023 The Author(s).